Eylea Market Outlook Report 2024-2033 | Size, Trends, Analysis, Insights, Overview

The eylea market size has grown strongly in recent years. It will grow from $7.8 billion in 2023 to $8.19 billion in 2024 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to diabetic macular edema (dme) prevalence, clinical efficacy and safety profile, competition with other anti-vegf therapies, approval for various retinal conditions, shift towards intravitreal injections..

The eylea market size is expected to see strong growth in the next few years. It will grow to $10.16 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to emerging therapeutic indications, introduction of biosimilar competition, increasing awareness and diagnosis, real-world evidence and post-market studies, patient preference for less frequent injections.. Major trends in the forecast period include advancements in imaging technologies, telemedicine and remote monitoring, patient assistance programs, advances in drug delivery technologies, retinal imaging technologies, clinical trials for new indications..

Market Overview -
Eylea is a type of drug injected into the eye that helps slow vision loss and certain other diseases by blocking the leaking and growth of fluid from abnormal blood vessels from the back of the eye. It is used to treat age-related macular degeneration (AMD).

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=9155&type=smp

Eylea Market Thrives On Addressing The Rise In Ocular Diseases
The increasing prevalence of ocular diseases is expected to propel the Eylea market. Ocular diseases refer to an eye condition that interferes with the ability of the eye properly function and negatively affects the vision and clarity of the eye. They often don't have any symptoms until they have become very advanced. Eylea treats conditions such as ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, which damages the retina or macula that affects the vision. Eylea blocks the protein that develops new weaker blood vessels and slows down the retina's swelling caused by a blockage in the blood vessels. For instance, in October 2022, according to the BrightFocus Foundation, a US-based nonprofit organization dedicated to advancing research and support for macular degeneration and glaucoma, there were currently 80 million individuals with glaucoma across the globe, with a projected increase to more than 111 million by the year 2040. Therefore, the increasing prevalence of ocular diseases is driving the Eylea market.

Competitive Landscape -
Major companies operating in the eylea market report are Regeneron Pharmaceuticals Inc., Bayer AG, Santen Pharmaceutical Co Ltd, Momenta Pharmaceuticals Inc., Novartis AG, Mylan NV, Vertex Pharmaceuticals Incorporated, Alvotech Switzerland AG, Sanofi SA, F Hoffmann-La Roche AG, PV Pharma, Alteogen Inc., Viatris Inc., Biocon Biologics Limited, Nexus Lifecare Pvt Ltd, AbbVie Inc., Alcon Inc., Alkem Laboratories Ltd., Intas Pharmaceuticals Ltd., Amgen Inc., Apotex Inc., Aurobindo Pharma Ltd., Lupin Ltd., Biogen Inc., Bristol-Myers Squibb Company, Cipla Ltd, Dr. Reddy's Laboratories Ltd, Merck & Co. Inc., Fresenius Kabi AG, Hikma Pharmaceuticals PLC .

Research And Development Elevate The Eylea Market
Research and developments are a key trend gaining popularity in the eylea market. Developing cutting-edge technical solutions is a top priority for the major industry players in eylea. For instance, in August 2023, Regeneron Pharmaceuticals, Inc., a US-based global biotechnology company developing medicine for serious diseases, received US FDA approval for Eylea HD (aflibercept) injection 8 mg to address patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). The administration schedule involves an initial period of every four weeks for the first three months across all indications, followed by adjusted intervals of every eight to 16 weeks for wAMD and DME, and every eight to 12 weeks for diabetic retinopathy.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/eylea-global-market-report

Key Segments -

The eylea market covered in this report is segmented -

1) By Product: Prefilled Syringe Package, Vial Package
2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders
3) By Application: Hospitals, Retail Pharmacy, Other Applications

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

"Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model "

"Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps"

This release was published on openPR.